Gilead Sciences Now Holds 14.75% of Galapagos Shares

Transparency notification to Galapagos NV

- Gilead Sciences, Inc.

crosses a 10% threshold of Galapagos' voting rights, to a 14.75% shareholding in Galapagos. Pursuant to Belgian transparency legislation1, Galapagos NV ("Galapagos") and Gilead Sciences, Inc. ("Gilead") have filed a joint transparency notification on 22 January 2016.  The transparency notification announces that Gilead, as a result of its entirely-controlled subsidiary Gilead Biopharmaceutics Ireland Unlimited Company subscribing to a capital increase and thus receiving 6,760,701 new Galapagos shares on 19 January 2016, indirectly holds 14.75% of the current 45,837,043 outstanding Galapagos shares.  Gilead therefore crossed a 10% threshold of Galapagos' voting rights on 19 January 2016.  Furthermore, Galapagos and Gilead are acting in concert as a result of standstill and lock-up provisions with respect to Galapagos shares held by Gilead contained in their global collaboration agreement for the development and commercialization of the JAK1-selective inhibitor filgotinib.  The full transparency notice is available for viewing on the Galapagos website. About Galapagos Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action.  Our pipeline comprises three Phase 2, four Phase 1, five pre-clinical, and 20 discovery studies in